AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30054099
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide group (2-visit treatment)
Trial: 29146633
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of antibiotics (including an option for complete outpatient therapy)
Trial: 29146633
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of antibiotics
Trial: 26396054
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of daily walnut intake for 4 weeks
Trial: 26396054
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of daily walnut intake for 4 weeks
Trial: 18471953
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (Laser)
Trial: 17071205
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (3 g/d) and vitamin D (1 g/d) for 2 weeks
Trial: 11095326
Drug: Alendronate 40
RxNorm normalized name: ALENDRONATE 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 40 mg/day (N = 90)
Trial: 11095326
Drug: Risedronate 30
RxNorm normalized name: risedronate 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 30 mg/day (N = 89)
Trial: 11095326
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with aspirin 650 mg q.i.d. for the last 7 days (N = 20)
Trial: 9366932
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg bolus followed by 2 micrograms/kg/min infusion for 24 hours, then 1 microgram/kg/min for 48 hours)
Trial: 1564126
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium 120 mg daily for 28 days
Trial: 1564126
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium 120 mg daily
Trial: 27136251
Drug: Pittsburgh Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pittsburgh Sleep Quality Index (PSQI) administered at baseline, 2, 6, and 12 months after transplant; 12-month PSQI categorized good versus poor sleepers.
Trial: 24931322
Drug: Vatreptacog alfa
RxNorm normalized name: Vatreptacog alfa
DrugBank: Vatreptacog alfa (DB12409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatreptacog alfa (80 μg kg(‐1), one to three doses)
Trial: 24931322
Drug: rFVIIa (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (90 μg kg(‐1), one to three doses)
Trial: 12803872
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ivermectin and albendazole
Trial: 7019839
Drug: Theophylline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (250 mg fast release)
Trial: 7019839
Drug: Terbutaline (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (2.5 mg)
Trial: 7400476
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Theophylline and Terbutaline
Trial: 7019839
Drug: Theophylline or
RxNorm normalized name: theophylline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline or Terbutaline (alone or in combination)
Trial: 28074556
Drug: Isavuconazole (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (therapeutic or supratherapeutic doses daily for 11 days after a 2-day loading dose)
Trial: 28074556
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg q.d.)
Trial: 26621254
Drug: Chemoradiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy with cisplatin and 9 l of saline solution during hydration in the first, fourth, and seventh week
Trial: 21135055
Drug: High-dose platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose platinum-based chemotherapy (HD-PB)
Trial: 31956037
Drug: Conventional anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anthracycline-based chemotherapy
Trial: 17089581
Drug: Microalbuminuria assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microalbuminuria assessment after one month of treatment
Trial: 15587750
Drug: Right internal
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right internal jugular group (G-RIJV)
Trial: 15587750
Drug: Left subclavian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left subclavian group (G-LSCV)
Trial: 15587750
Drug: Right subclavian
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right subclavian group (G-RSCV)
Trial: 15587750
Drug: Left internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left internal jugular vein group (G-LIJV)
Trial: 9258415
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement therapy (0.125 IU/kg per week for the first 4 weeks, then 0.25 IU/kg per week)
Trial: 8276025
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 5-15 micrograms/kg per min
Trial: 8276025
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at 5-15 micrograms/kg per min
Trial: 3106656
Drug: Glyburide, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide, 20 mg/d (plus insulin)
Trial: 3106656
Drug: Placebo (plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plus insulin)
Trial: 30553231
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (500 mL/d)
Trial: 28986984
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Cor a 1 and Cor a 9
Trial: 27733375
Drug: Three preoperative
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three preoperative cycles of epirubicin 120 mg/m2 and ifosfamide 9 g/m2 (Arm A)
Trial: 27733375
Drug: Five cycles
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five cycles of adjuvant chemotherapy (Arm B)
Trial: 27733375
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of chemotherapy (Arm A)
Trial: 27733375
Drug: Five cycles
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five cycles of chemotherapy (Arm B)
Trial: 2574045
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to therapy
Trial: 15749318
Drug: Other preparations
RxNorm normalized name: other preparations, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other preparations applied for 1 min
Trial: 15749318
Drug: Sterillium applied
RxNorm normalized name: Trillium erectum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterillium applied for 1.5 min (2 x 3 mL)
Trial: 11867404
Drug: Epinephrine‐15 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine‐15 group (3 mL of 1.5% lidocaine containing 15 microg epinephrine)
Trial: 11867404
Drug: Epinephrine‐10 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine‐10 group (2 mL of test dose)
Trial: 11867404
Drug: Epinephrine‐5 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine‐5 group (1 mL of test dose)
Trial: 11049908
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group (3 mL of normal saline IV)
Trial: 7781586
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg at a daily dosage of 100 mg t.i.d. (25 mg - 25 mg - 50 mg)
Trial: 7781586
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg at a daily dosage of 4 mg t.i.d. (1 mg - 1 mg - 2 mg)
Trial: 28550023
Drug: CC 100
RxNorm normalized name: HYDROCORTISONE NA SUCC 1000MG/VI INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC 100 mg
Trial: 23363494
Drug: Custodiol HTK
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custodiol HTK solution
Trial: 19748405
Drug: Local manipulative
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local manipulative therapy combined with exercise and soft tissue treatment
Trial: 19748405
Drug: Full kinetic
RxNorm normalized name: Kineticream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full kinetic chain manipulative therapy combined with exercise and soft tissue treatment
Trial: 15627856
Drug: Brief Dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Dynamic Therapy (BDT)
Trial: 12118806
Drug: Slow load
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow load amiodarone (7 g oral amiodarone more than 10 days starting 5 days before OHS; n = 56)
Trial: 12118806
Drug: Fast load
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast load amiodarone (6 g oral amiodarone more than 6 days starting 1 day before OHS; n = 64)
Trial: 10403145
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/day for first 6 weeks, adjusted to 20-50 mg/day thereafter)
Trial: 10403145
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day for first 6 weeks, adjusted to 20-80 mg/day thereafter)
Trial: 2129373
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of IV beta blocker (metoprolol)
Trial: 2129373
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of beta blocker (starting on Day 6)
Trial: 7404301
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg doxycycline and 2 g tinidazole (single preoperative dose)
Trial: 7404301
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg gentamicin and 600 mg clindamycin (three doses with eight hour intervals, starting one hour preoperatively)
Trial: 26051455
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of misoprostol
Trial: 23812769
Drug: Single-dose intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intraoperative radiation therapy (IORT)
Trial: 23812769
Drug: 6-week whole-breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week whole-breast external-beam radiation therapy (WB-EBRT)
Trial: 16707395
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg daily for 2 weeks
Trial: 2284219
Drug: Lornoxicam 4
RxNorm normalized name: lornoxicam 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 4 mg twice daily for 14 days
Trial: 2284219
Drug: Lornoxicam 4
RxNorm normalized name: lornoxicam 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 4 mg, indomethacin 50 mg, or placebo twice daily for 29 days
Trial: 2284219
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg twice daily for 29 days
Trial: 2284219
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 29 days
Trial: 7457801
Drug: Controlled mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled mechanical ventilation, relaxation, intravenous anaesthesia, at least 1 1 fluid replacement, careful monitoring
Trial: 26970404
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (single-dose)
Trial: 26677665
Drug: SGRS Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGRS Chinese herbs as adjuvant therapy
Trial: 23013325
Drug: Monthly alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly alcohol consumption by mothers
Trial: 22198102
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 100 mg aspirin and 200 mg cilostazol
Trial: 18204334
Drug: Aripiprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (2 mg/d, titrated to a maximum of 30 mg/d at day 28)
Trial: 12562459
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil (90 mg)
Trial: 12562459
Drug: Caraway oil
RxNorm normalized name: Caraway Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caraway oil (50 mg)
Trial: 12562459
Drug: n-butylscopolamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-butylscopolamine (10 mg)
Trial: 6324586
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (20 cc/kg weekly doses before and after transplantation)
Trial: 25533447
Drug: Palonosetron (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.75 mg on day 1)
Trial: 25533447
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg twice daily on days 1 through 5)
Trial: 25533447
Drug: Combination antiemetic
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiemetic therapy (5‐HT3 receptor antagonists, NK‐1RAs, and dexamethasone)
Trial: 20689518
Drug: Subcutaneous rEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rEPO at 250 units kg(‐1) per dose, three times weekly for 6 weeks
Trial: 20689518
Drug: Subcutaneous rEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rEPO at 750 units kg(‐1) per dose, once weekly for 6 weeks
Trial: 19004650
Drug: Tonic rectal
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonic rectal electrical stimulation
Trial: 19004650
Drug: Tonic rectal
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonic rectal distension stimulation
Trial: 16933087
Drug: High fidelity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fidelity Integrated Dual Disorders Treatment program
Trial: 11359482
Drug: Tooth-implant connected
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth-implant connected prostheses
Trial: 11359482
Drug: Freestanding implant-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freestanding implant-supported prostheses
Trial: 11359482
Drug: Rigid tooth-implant
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigid tooth-implant connected prostheses
Trial: 3436154
Drug: Isoxicam (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoxicam (400 mg single dose)
Trial: 3436154
Drug: Isoxicam (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoxicam (repeated dosing)
Trial: 21733727
Drug: Amikacin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 7.5 mg/kg every 8 h (MDD)
Trial: 21733727
Drug: Amikacin 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 22.5 mg/kg as a single dose (ODD)
Trial: 15297066
Drug: Fluarix (1/10th
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluarix (1/10th dose)
Trial: 15297066
Drug: Fluarix (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluarix (full dose)
Trial: 9579717
Drug: Roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 300 mg once daily for 8-10 days
Trial: 9579717
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg once daily for 8-10 days
Trial: 7900711
Drug: Lorazepam (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (as an adjunct to metoclopramide, dexamethasone, and clemastine)
Trial: 24793528
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg conbercept (PRN)
Trial: 24793528
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg conbercept (Q1M)
Trial: 24793528
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg conbercept (PRN)
Trial: 24793528
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg conbercept (Q1M)
Trial: 24793528
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg conbercept
Trial: 24793528
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg conbercept
Trial: 22573504
Drug: Control (occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (occupational therapy)
Trial: 17332788
Drug: Insulin stimulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin stimulation alone
Trial: 17332788
Drug: Insulin stimulation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin stimulation with superimposed exercise
Trial: 29778481
Drug: Anti-IL-10 egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-10 egg yolk antibodies (MAB, n = 71)
Trial: 29778481
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without anti-IL-10 antibodies (MEP, n = 62)
Trial: 29778481
Drug: Anti-IL-10 egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-10 egg yolk antibodies (MAB)
Trial: 21983163
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of 10mg rosuvastatin
Trial: 21983163
Drug: Alternate-day dosing
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day dosing of 10mg rosuvastatin
Trial: 18445991
Drug: LOS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS group (losartan 25 mg alone)
Trial: 18445991
Drug: LOS+BUC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS+BUC group (losartan 25 mg after bucolome 300 mg for 7 days)
Trial: 18445991
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (losartan 10 mg/kg for 14 days)
Trial: 18445991
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (losartan 10 mg/kg and bucolome 50 mg/kg for 14 days)
Trial: 16330675
Drug: Doxorubicin-cisplatin (AP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin-cisplatin (AP) chemotherapy (60 mg/m2 doxorubicin and 50 mg/m2 cisplatin every 3 weeks for seven cycles, followed by one cycle of cisplatin)
Trial: 16330675
Drug: Doxorubicin-cisplatin (AP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin-cisplatin (AP) chemotherapy
Trial: 14616410
Drug: Voriconazole +
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole + Warfarin
Trial: 14616410
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Warfarin
Trial: 8928327
Drug: Estimation according
RxNorm normalized name: clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estimation according to E.G. Lowrei
Trial: 8928327
Drug: Estimation according
RxNorm normalized name: clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estimation according to L. Garred et. al.
Trial: 6144829
Drug: Intradermal HDCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal HDCV (0.1 ml doses)
Trial: 6144829
Drug: Intramuscular HDCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular HDCV (1.0 ml doses)